secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193125-23-035865
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M
--------------------------------------------------------------------------------

- Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.
- Acquires Amnis imaging and Guava flow cytometers; >60% of FCI employees are commercial, boosting Cytek's sales and service.
- Acquisition aligns with DiaSorin's strategic priorities; Cytek expands global footprint and adds entry-level instrument options.
- Cytek to host investor conference call Feb 13 at 4:30 PM ET; details at investors.cytekbio.com.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/0001193125-23-035865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/d446963d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-035865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer